Nearly two years after Takeda pulled its US marketing application for a vaccine against dengue fever, MSD has advanced a rival shot into phase 3. The international MOBILIZE-1 trial is looking at a ...
A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the ...
With every instalment in the Borderlands series, Shift codes have been Gearbox's chosen way to dole out post-launch loot and rewards. On a pretty consistent basis, Gearbox gives away these freebies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback